Susquehanna International Group
NVCR icon

Susquehanna International Group’s NovoCure NVCR Stock Holding History

Susquehanna International Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.97M Buy
639,400
+374,200
+141% +$4.67M ﹤0.01% 3674
2025
Q4 		$3.43M Buy
265,200
+169,900
+178% +$2.18M ﹤0.01% 4642
2025
Q3 		$1.23M Buy
95,300
+37,800
+66% +$505K ﹤0.01% 6850
2025
Q2 		$1.02M Sell
57,500
-21,500
-27% -$375K ﹤0.01% 7375
2025
Q1 		$1.41M Sell
79,000
-105,800
-57% -$2.4M ﹤0.01% 6374
2024
Q4 		$5.51M Buy
184,800
+29,300
+19% +$620K ﹤0.01% 3446
2024
Q3 		$2.43M Buy
155,500
+10,100
+7% +$183K ﹤0.01% 4903
2024
Q2 		$2.49M Sell
145,400
-94,700
-39% -$1.67M ﹤0.01% 4658
2024
Q1 		$3.75M Sell
240,100
-147,300
-38% -$2.17M ﹤0.01% 4117
2023
Q4 		$5.78M Buy
387,400
+344,200
+797% +$4.61M ﹤0.01% 3468
2023
Q3 		$698K Sell
43,200
-205,100
-83% -$5.91M ﹤0.01% 7456
2023
Q2 		$10.3M Buy
248,300
+155,600
+168% +$9.66M ﹤0.01% 2473
2023
Q1 		$5.57M Sell
92,700
-128,000
-58% -$10.2M ﹤0.01% 3296
2022
Q4 		$16.2M Buy
220,700
+77,200
+54% +$5.81M ﹤0.01% 1729
2022
Q3 		$10.9M Sell
143,500
-49,100
-25% -$3.83M ﹤0.01% 2042
2022
Q2 		$13.4M Buy
192,600
+44,000
+30% +$3.31M ﹤0.01% 1847
2022
Q1 		$12.3M Sell
148,600
-25,100
-14% -$1.85M ﹤0.01% 2278
2021
Q4 		$13M Sell
173,700
-191,800
-52% -$19.3M ﹤0.01% 2356
2021
Q3 		$42.5M Buy
365,500
+253,400
+226% +$38.3M 0.01% 1289
2021
Q2 		$24.9M Sell
112,100
-30,100
-21% -$5.86M ﹤0.01% 1796
2021
Q1 		$18.8M Sell
142,200
-225,800
-61% -$35.7M ﹤0.01% 1948
2020
Q4 		$63.7M Buy
368,000
+6,400
+2% +$876K 0.01% 880
2020
Q3 		$40.3M Sell
361,600
-130,400
-27% -$10.4M 0.01% 986
2020
Q2 		$29.2M Buy
492,000
+74,100
+18% +$4.87M 0.01% 1148
2020
Q1 		$28.1M Buy
417,900
+169,200
+68% +$13.4M 0.01% 975
2019
Q4 		$21M Buy
248,700
+42,200
+20% +$3.41M 0.01% 1370
2019
Q3 		$15.4M Buy
206,500
+44,400
+27% +$3.55M 0.01% 1546
2019
Q2 		$10.3M Buy
162,100
+108,200
+201% +$5.48M ﹤0.01% 1855
2019
Q1 		$2.6M Sell
53,900
-9,300
-15% -$448K ﹤0.01% 3371
2018
Q4 		$2.12M Sell
63,200
-10,400
-14% -$380K ﹤0.01% 3441
2018
Q3 		$3.86M Buy
73,600
+9,400
+15% +$374K ﹤0.01% 3013
2018
Q2 		$2.01M Sell
64,200
-38,900
-38% -$1.08M ﹤0.01% 4007
2018
Q1 		$2.25M Sell
103,100
-24,700
-19% -$531K ﹤0.01% 3703
2017
Q4 		$2.58M Sell
127,800
-34,800
-21% -$670K ﹤0.01% 3481
2017
Q3 		$3.23M Buy
162,600
+79,900
+97% +$1.57M ﹤0.01% 3118
2017
Q2 		$1.43M Buy
82,700
+72,500
+711% +$936K ﹤0.01% 4526
2017
Q1 		$83K Sell
10,200
-6,000
-37% -$43.3K ﹤0.01% 8460
2016
Q4 		$127K Sell
16,200
-21,900
-57% -$176K ﹤0.01% 8960
2016
Q3 		$325K Buy
38,100
+20,200
+113% +$184K ﹤0.01% 6795
2016
Q2 		$209K Sell
17,900
-23,500
-57% -$294K ﹤0.01% 7541
2016
Q1 		$599K Sell
41,400
-17,200
-29% -$247K ﹤0.01% 6084
2015
Q4 		$1.31M Buy
+58,600
New +$1.4M ﹤0.01% 4865

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Susquehanna International Group's NVCR Position: Q1 2026 in Review

Susquehanna International Group reduced its NovoCure (NVCR) stake by 3.3% in Q1 2026, selling an estimated $83.4K and leaving 197,375 shares worth $2.15M. The position accounts for ﹤0.01% of the portfolio, ranked #6007.

Susquehanna International Group first reported a position in NVCR in Q1 2016 and has held it in 30 quarters since. The position peaked at $56M in Q4 2020. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Susquehanna International Group held 197,375 shares of NovoCure worth $2.15M as of Q1 2026.
  • Susquehanna International Group sold 6,678 NovoCure shares in Q1 2026, an estimated $83.4K.
  • NovoCure made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6007 holding.
  • Susquehanna International Group first reported a position in NovoCure in Q1 2016 and has held it in 30 quarters since.
  • Susquehanna International Group's NovoCure position peaked at $56M in Q4 2020.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.